Foghorn Therapeutics (FHTX) vs OnKure Therapeutics (OKUR)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
OnKure Therapeutics (OKUR) has outperformed Foghorn Therapeutics (FHTX) over the past year, gaining 4.7% versus a loss of 62.8%. Over five years, FHTX leads with a -87.4% price change compared with -96.2% for OKUR. OnKure Therapeutics is the larger company by market cap ($111.2 million vs $103.1 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | FHTX | OKUR |
|---|---|---|
| Share price | $1.72 | $2.70 |
| Market cap | $103.14M | $111.21M |
| 1-day change | -3.37% | -2.17% |
| YTD return | -68.15% | -6.90% |
| 1-year return | -62.77% | +4.65% |
| 5-year return | -87.36% | -96.16% |
| P/E ratio (TTM) | 19.11 | — |
| EPS (TTM) | $0.09 | $-2.26 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $30.91M | — |
| Revenue growth (YoY) | +36.75% | — |
| Net income (latest FY) | $-74.28M | $-59.52M |
| Operating margin | -279.49% | — |
| Net margin | -240.33% | — |
| 52-week high | $7.61 | $5.38 |
| 52-week low | $1.66 | $2.01 |
| Distance from 52-week high | -77.40% | -49.81% |
| Analyst consensus | buy | none |
| Avg. price target upside | +142.44% | +464.81% |
| Average volume | 843.73K | 335.78K |
| Shares outstanding | 59.96M | 40.50M |
| Employees | 106 | 45 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- OKUR has outperformed FHTX by 67.4 percentage points over the past year.
About Foghorn Therapeutics
FHTX stock →Foghorn Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of medicines targeting genetically determined dependencies within the chromatin regulatory system in the United States. The company uses its proprietary Gene Traffic Control platform to identify, validate, and potentially drug targets within the system.
Health Care · Biotechnology: Pharmaceutical Preparations · 106 employees
About OnKure Therapeutics
OKUR stock →OnKure Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of precision medicines that target biologically validated drivers of cancers and other diseases. Its lead product candidate includes OKI-219, a selective inhibitor of phosphoinositide 3-kinase alpha (PI3Ka) harboring the H1047R mutation that is in Phase 1 clinical trial for the treatment of solid tumors, including breast cancer.
Health Care · Biotechnology: Pharmaceutical Preparations · 45 employees
FHTX vs OKUR FAQ
Which is bigger, Foghorn Therapeutics or OnKure Therapeutics?
OnKure Therapeutics (OKUR) is larger, with a market capitalization of $111.21M compared with $103.14M for Foghorn Therapeutics (FHTX).
Which stock has performed better over the past year, FHTX or OKUR?
OKUR returned +4.65% over the past 12 months, compared with -62.77% for FHTX (price return, excluding dividends). Past performance does not predict future results.
Are Foghorn Therapeutics and OnKure Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.